Pfizer Inc and partner BioNTech SE said on Friday they had applied to the European health regulator to extend the marketing authorization for their coronavirus vaccine for use in adolescents aged 12 to 15.
The companies filed a similar request in the United States earlier this month for the vaccine, which is already authorized for use in people from 16 years of age in both the United States and the European Union.
For the latest headlines, follow our Google News channel online or via the app.
The submissions are based on positive data from a late-stage clinical trial that enrolled 2,260 participants aged 12 to 15, the companies said.
US Centers for Disease Control and Prevention director Rochelle Walensky told ABC News earlier this month that she expected the vaccine to be authorized for 12- to 15-year-olds by mid-May.
Read more:
BioNTech expects vaccine trial results for babies, other EMA approvals soon
Tens of millions of J&J coronavirus vaccine doses sit on shelves awaiting FDA review
Vaccinating more than anywhere else, China still needs to speed up to reach target
Also Read
-
BioNTech expects vaccine trial results for babies, other EMA approvals soon
BioNTech expects results by September from trials testing the COVID-19 vaccine that it and Pfizer have developed in babies as young as six months old, ... Coronavirus -
BioNTech founder says Europe will reach herd immunity against COVID-19 this summer
Europe can achieve herd immunity against the coronavirus within three to four months, the head of German pharmaceutical company BioNTech, which ... Coronavirus -
EU seals deal with Pfizer-BioNTech for up to 1.8 bln doses of coronavirus vaccine
The European Union sealed a deal with Pfizer-BioNTech for the supply of up to 1.8 billion doses of their COVID-19 vaccine, an EU official told ... Coronavirus
